Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


  • Nikolai Dyrberg Loft, University of Copenhagen
  • ,
  • Alexander Egeberg, University of Copenhagen
  • ,
  • Mads Kirchheiner Rasmussen
  • ,
  • Lars Erik Bryld, Zealand University Hospital
  • ,
  • Robert Gniadecki, Bispebjerg Hospital, Bispebjerg
  • ,
  • Tomas Norman Dam, Dermatology Clinic, Nykøbing Falster, Zealand Region.
  • ,
  • Lars Iversen
  • Lone Skov, University of Copenhagen

The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based on data from the Danish national registry (DERMBIO), this study investigated the correlation between changes in PASI and DLQI in a cohort of patients with moderate-to-severe psoriasis treated with biologics or apremilast using Spearman’s rank correlation analyses. The correlation analysis of 1,677 patients, of whom 276 had available data after 5 years, showed weak-to-moderate correlation between PASI and DLQI during a 5-year period and between changes in PASI and DLQI: 0.58 (p < 0.0001) for baseline to 3 months and 0.42 (p < 0.0001) for 3 to 12 months. The first question on “Symptoms and feelings” made up the largest proportion of the overall DLQI. The correlation between PASI and DLQI is weak-to-moderate and varies over time. Changes in PASI correlate weak-to-moderately with changes in DLQI during the first 12 months of treatment, with symptoms being the most important factor contributing to impaired quality of life.

TidsskriftActa Dermato-Venereologica
Sider (fra-til)1224-1230
Antal sider7
StatusUdgivet - 2019

Se relationer på Aarhus Universitet Citationsformater

ID: 173067741